Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Single Ascending Dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants

NCT07220889
View directory record Official record
Conditions
Safety After Oral Intake
Interventions
MDI-2517 800mg, Placebo, MDI-2517 1600mg, MDI-2517 2400mg, MDI-2517 3600mg
Drug · Other
Lead sponsor
MDI Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3127760 in Healthy Participants

NCT01968070
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3127760, Celecoxib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 5, 2026, 8:37 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

NCT06951880
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4916, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT05859724
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NM26-2198, Placebo
Biological · Other
Lead sponsor
Yellow Jersey Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fountain Valley, California • Glendale, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3461767 in Healthy Participants

NCT04352114
View directory record Official record
Conditions
Healthy
Interventions
LY3461767 - SC, LY3461767 - IV, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral CXA-10 Study in Healthy Volunteers

NCT02313064
View directory record Official record
Conditions
Chronic Kidney Injury
Interventions
CXA-10, CXA-10 placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

NCT02792998
View directory record Official record
Conditions
Healthy
Interventions
IW-1701, Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 8:37 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

NCT07224399
View directory record Official record
Conditions
Healhty, Overweight or Obesity
Interventions
BGM1812, Placebo
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ENA-001 for Opioid Induced Respiratory Depression

NCT06967259
View directory record Official record
Conditions
Respiratory Depression
Interventions
ENA-001, Placebo Comparator
Drug
Lead sponsor
Enalare Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of E2086 in Healthy Adult Participants

NCT06481488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

NCT06927960
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
AH-001 or placebo
Drug
Lead sponsor
AnHorn Medicines Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRX002 in Healthy Subjects

NCT02095171
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PRX002, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

NCT03746067
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-134, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 5, 2026, 8:37 AM EDT
Recruiting Phase 1 Interventional

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3954068, Placebo, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3561774 in Participants With Dyslipidemia

NCT04644809
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Cypress, California • Long Beach, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 5, 2026, 8:37 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

NCT07801300
View directory record Official record
Conditions
Healthy Volunteers, C-Reactive Protein
Interventions
LY5625575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 5, 2026, 8:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Intravenous Treatment for Influenza

NCT01375985
View directory record Official record
Conditions
Influenza
Interventions
AVI-7100, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 5, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 5, 2026, 8:37 AM EDT